Establishment and application of a determination method for plasma concentrations of venetoclax， busulfan and voriconazole in patients with acute myeloid leukemia

ZHANG Zhenhua; ZHANG Mengru; GUO Aoxiang; CHEN Hui; XIANG Shijian; ZHOU Benjie; GE Bingchen

doi:10.6039/j.issn.1001-0408.2026.10.15

您当前的位置：

首页 >

文章列表页 >

Establishment and application of a determination method for plasma concentrations of venetoclax， busulfan and voriconazole in patients with acute myeloid leukemia

更新时间：2026-05-26

- Establishment and application of a determination method for plasma concentrations of venetoclax， busulfan and voriconazole in patients with acute myeloid leukemia
- ZHONGGUO YAOFANG Vol. 37, Issue 10, Pages: 1323-1328(2026)
- 作者机构：
  
  1.中山大学第七附属医院（深圳）药学部，广东深圳;518107
  2.中山大学药学院（深圳），广东深圳　518107
  3.深圳中药活性物质筛选与转化研究重点实验室，广东深圳　518107
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.10.15
  CLC： R969
- Received：22 December 2025，
  
  Revised：2026-04-21，
  
  Accepted：22 April 2026，
  
  Published：30 May 2026
- 稿件说明：
移动端阅览
张振华,张梦茹,郭傲翔,等.AML患者血浆中维奈克拉、白消安和伏立康唑浓度测定方法的建立与应用 ^Δ[J].中国药房,2026,37(10):1323-1328. DOI: 10.6039/j.issn.1001-0408.2026.10.15.

ZHANG Zhenhua,ZHANG Mengru,GUO Aoxiang,et al.Establishment and application of a determination method for plasma concentrations of venetoclax， busulfan and voriconazole in patients with acute myeloid leukemia[J].ZHONGGUO YAOFANG,2026,37(10):1323-1328.
张振华,张梦茹,郭傲翔,等.AML患者血浆中维奈克拉、白消安和伏立康唑浓度测定方法的建立与应用 ^Δ[J].中国药房,2026,37(10):1323-1328. DOI: 10.6039/j.issn.1001-0408.2026.10.15. DOI：

ZHANG Zhenhua,ZHANG Mengru,GUO Aoxiang,et al.Establishment and application of a determination method for plasma concentrations of venetoclax， busulfan and voriconazole in patients with acute myeloid leukemia[J].ZHONGGUO YAOFANG,2026,37(10):1323-1328. DOI： 10.6039/j.issn.1001-0408.2026.10.15.

摘要

目的

建立同时测定急性髓系白血病（AML）患者血浆中维奈克拉、白消安和伏立康唑浓度的方法并应用于临床。

方法

血浆样品经乙腈沉淀蛋白后，分别以维奈克拉-D

、白消安-D

、泊沙康唑为内标，采用液相色谱-串联质谱（LC-MS/MS）法检测。以Phenomenex Kinetex

为色谱柱，以0.1%甲酸溶液（含2 mmol/L乙酸铵）-0.1%甲酸乙腈溶液为流动相进行梯度洗脱；流速为0.8 mL/min；柱温为40 ℃；进样量为5 μL；运行时间为3.10 min；采用电喷雾离子源，以多反应监测方式进行正离子扫描，用于定量分析的离子对包括

868.4→636.3（维奈克拉）、

264.1→151.1（白消安）、

350.1→224.0（伏立康唑）等。采用上述LC-MS/MS法测定10例联合用药AML患者体内维奈克拉、伏立康唑的血药浓度和5例行异基因造血干细胞移植预处理患者体内白消安的血药浓度。

结果

维奈克拉、白消安、伏立康唑检测质量浓度的线性范围分别为50～10 000、15～3 000、50～10 000 ng/mL（

≥0.999 0），定量下限分别为50、15、50 ng/mL；3种待测药物的日内、日间精密度的RSD均低于10%，准确度（相对误差）为－10.00%～12.96%；平均提取回收率为92.54%～100.95%，平均基质效应为89.98%～101.49%，稀释可靠性可覆盖试验样品所用的稀释倍数，稳定性试验的相对误差绝对值均不高于16.25%。纳入患者体内维奈克拉、白消安、伏立康唑的血药浓度分别为496.20～4 250.45、233.48～2 002.28、475.51～5 710.18 ng/mL。

结论

所建LC-MS/MS法快速、灵敏、操作简便，可用于AML患者维奈克拉、白消安和伏立康唑血药浓度治疗药物监测。

Abstract

OBJECTIVE

To establish a method for simultaneous determination of venetoclax， busulfan and voriconazole in plasma of patients with acute myeloid leukemia （AML）， and apply it clinically.

METHODS

Plasma samples were subjected to protein precipitation using acetonitrile and subsequently analyzed by liquid chromatography-tandem mass spectrometry （LC-MS/MS） using venetoclax-D

， busulfan-D

and posaconazole as internal standards. The separation was performed on a Phenomenex Kinetex

column with a mobile phase composed of 0.1% formic acid solution （2 mmol/L ammonium acetate）-0.1% formic acid in acetonitrile （gradient elution） at a flow rate of 0.8 mL/min. The column temperature was set at 40 ℃， the sample size was 5 μL， and the total run time was 3.10 min. An electrospray ionization source was employed， and positive ion scanning was conducted using multiple reaction monitoring mode. The ion pairs used for quantitative analysis included

m/z

868.4→636.3 （venetoclax），

m/z

264.1→151.1 （busulfan）， and

m/z

350.1→224.0 （voriconazole）. The above LC-MS/MS method was adopted to determine plasma concentrations of venetoclax and voriconazole in 10 AML patients， as well as plasma concentration of busulfan in 5 patients undergoing conditioning treatment for allogeneic hematopoietic stem cell transplantation.

RESULTS

The linear ranges of venetoclax， busulfan and voriconazole were 50-10 000， 15-3 000 and 50-10 000 ng/mL， respectively （

≥0.999 0）， with lower limits of quantification of 50， 15 and 50 ng/mL， respectively. The RSDs of intra-day and inter-day precision tests for all three analytes were all less than 10%， with accuracy （relative errors） ranging from －10.00% to 12.96%. The average extraction recovery ranged from 92.54% to 100.95%， and the average matrix effect was 89.98%-101.49%. Dilution reliability covered all dilution factors used in the test

samples， and the absolute values of relative errors in stability tests were all≤16.25%. The plasma concentrations of venetoclax， busulfan and voriconazole in enrolled patients were 496.20-4 250.45， 233.48-2 002.28 and 475.51-5 710.18 ng/mL， respectively.

CONCLUSIONS

The LC-MS/MS method established in this study is rapid， sensitive and easy to operate， and can be used for the therapeutic drug monitoring of venetoclax， busulfan and voriconazole.

关键词

Keywords

references

YIN W ， YAN X Y ， CAI J Y ， et al . Incidence，mortality，and survival associated with acute leukaemia subtypes by age group in China：a population-based cancer registry analysis and cohort study [J ] . Lancet Haematol ， 2025 ， 12 （ 10 ）： e808 - e822 .

CHIESA S ， REGO E M ， TEICH V ， et al . Microcosting analysis of haematopoietic stem cell transplantation and chemotherapy with intermediate doses of cytarabine in the treatment of acute myeloid leukaemia [J ] . Hematol Transfus Cell Ther ， 2024 ， 46 （ Suppl 6 ）： S136 - S143 .

XIAO F ， GUO H X ， YAN X Q ， et al . Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia [J ] . Transpl Immunol ， 2024 ， 84 ： 102037 .

李晋文，徐燕，王晓丹，等 . 干细胞移植患者白消安暴露量的估算模型研究 [J ] . 中国药理学通报， 2024 ， 40 （ 6 ）： 1193 - 1198 .

FUKUMOTO A ， NARITA K ， IKEDA D ， et al . Safety and efficacy of venetoclax for acute myeloid leukaemia in real-world clinical practice [J ] . Jpn J Clin Oncol ， 2023 ， 53 （ 10 ）： 991 - 995 .

GARCIA J S ， KIM H T ， MURDOCK H M ， et al . Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML [J ] . Blood Adv ， 2024 ， 8 （ 4 ）： 978 - 990 .

POPAT U ， BASSETT R L ， ALOUSI A M ， et al . Myeloablative fractionated busulfan，fludarabine，cladribine，thiotepa and venetoclax （cladillac） conditioning regimen for very high-risk AML/MDS：a phase 2 trial [J ] . Blood ， 2024 ， 144 ： 506 - 506 .

GARCIA J S ， KIM H T ， MURDOCK H M ， et al . Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible，safe，and active [J ] . Blood Adv ， 2021 ， 5 （ 24 ）： 5536 - 5545 .

MUKHERJEE D ， BRACKMAN D J ， SULEIMAN A A ， et al . Impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics：a PBPK and population PK-informed analysis [J ] . J Clin Pharmacol ， 2023 ， 63 （ 1 ）： 119 - 125 .

DIELLA L ， BAVARO D F ， LOSETO G ， et al . Current therapies for chronic lymphocytic leukemia：risk and prophylaxis strategies for secondary/opportunistic infections [J ] . Expert Rev Hematol ， 2023 ， 16 （ 4 ）： 267 - 276 .

YANG Y L ， QIAN Z Y ， ZHAO Y ， et al . LC-MS/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid [J ] . Biomed Chromatogr ， 2023 ， 37 （ 12 ）： e5738 .

YANG X ， MEI C ， HE X Y ， et al . Quantification of venetoclax for therapeutic drug monitoring in Chinese acute mye-loid leukemia patients by a validated UPLC-MS/MS method [J ] . Molecules ， 2022 ， 27 （ 5 ）： 1607 .

CAFARO A ， PIGLIASCO F ， BAIARDI G ， et al . Development and validation of a novel LC-MS/MS method for a TDM-guided personalization of HSCT conditioning with high-dose busulfan in children [J ] . Biomedicines ， 2023 ， 11 （ 2 ）： 530 .

PROMMAS S ， PUANGPETCH A ， JENJIRATTITHIGARN N ， et al . Development and validation of voriconazole concentration by LC-MS-MS：applied in clinical implementation [J ] . J Clin Lab Anal ， 2017 ， 31 （ 1 ）： e22011 .

国家药典委员会 . 中华人民共和国药典：四部 [S ] . 2020年版. 中国医药科技出版社， 2020 ： 466 - 472 .

ALOMARI N ， KURDI A. ， ALGHAMDI M . et al . Therapeutic drug monitoring of busulfan in pediatric patients：a 5-year observational study [J ] . BMC Pharmacol Toxicol ， 2025 ， 26 （ 1 ）： 175 .

贾兰舟，窦颖 . 造血干细胞移植中儿童白消安群体药动学模型的建立及在治疗药物监测中的应用 [J ] . 中国临床药学杂志， 2022 ， 31 （ 12 ）： 940 - 945 .

GAO P ， ZHANG W ， FANG X S ， et al . Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients [J ] . J Pharm Biomed Anal ， 2023 ， 227 ： 115279 .

LIAO J ， FAN L ， LI Y ， et al . Recent advances in biomimetic nanodelivery systems：new brain-targeting strategies [J ] . J Control Release ， 2023 ， 358 ： 439 - 464 .

EISENMANN E D ， JIN Y ， WEBER R H ， et al . Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma，and its application to pharmacokinetic studies [J ] . J Chromatogr B Analyt Technol Biomed Life Sci ， 2020 ， 1152 ： 122176 .

ALNASSER A I ， HEFNAWY M M ， AL-HOSSAINI A M ， et al . LC-MS/MS method for the quantitation of decitabine and venetoclax in rat plasma after SPE：application to pharmacokinetic study [J ] . Saudi Pharm J ， 2023 ， 31 （ 9 ）： 101693 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

UPLC-MS/MS法测定人血浆中伏立康唑的浓度及其临床应用

Guidelines for the management of therapeutic drug monitoring

Construction of the research question system of the Guideline for the Management of Therapeutic Drug Monitoring based on modified Delphi method

Study on the influencing factors of venetoclax trough concentration and its association with efficacy in patients with acute myeloid leukemia

Establishment and clinical application of a method for the determination of tacrolimus concentration in human whole blood

Related Author

ZHONG Jiao

HAO Kun

PEI Zejun

LI Zhengxiang

MIAO Liyan

DUAN Rong

ZUO Xiaocong

ZHANG Xianglin

Related Institution

Institute of Evidence-Based Medicine， School of Basic Medical Sciences， Lanzhou University

Chinese Pharmacists Association

Dept. of Pharmacy， Peking University Third Hospital

West China Second University Hospital， Sichuan University

Dept. of Pharmacy， the Second Xiangya Hospital， Central South University

⁰